Neurogene Q4 2025 Earnings Report

Neurogene EPS Results

• Actual EPS: -$1.12
• Consensus EPS: -$1.20
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: N/A

Neurogene Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Neurogene Announcement Details

• Quarter: Q4 2025
• Date: 3/24/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Neurogene (NASDAQ:NGNE), Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances.

Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.